AbbVie has entered into a warrant agreement with Watertown, Massachusetts-based Kestrel Therapeutics, granting AbbVie an exclusive option to acquire the private company upon the completion of defined development and regulatory milestones, with the total potential value of the deal reaching up to USD 1.45 billion. The AbbVie Kestrel acquisition option is structured around KST-6051, Kestrel's oral small-molecule pan-KRAS inhibitor, which dosed its first patient in the Phase I FALCON trial on the same day the AbbVie strategic partnership was announced.
Deal Terms and Structure
The agreement is structured as a warrant combined with an exclusive acquisition option, a mechanism that allows AbbVie to fund KST-6051 drug development through early clinical stages while retaining the right to purchase Kestrel outright once defined milestones are met. The total potential value of up to USD 1.45 billion encompasses an upfront payment, future exercise payments tied to the warrant, and downstream development and regulatory milestones. The individual components of that aggregate figure were not separately itemized in the company's disclosure. Because the transaction is structured as a whole-company acquisition option rather than a territorial license, no geographic carve-outs were disclosed, and the implied scope of any eventual acquisition would be global. Closing of a full acquisition remains contingent on milestone achievement; no closing date has been announced.
KST-6051 Drug Development and Mechanism
KST-6051 is an oral small-molecule inhibitor designed to bind KRAS in both its GTP-bound active state and its GDP-bound inactive state, providing coverage across the oncogenic signaling cycle. The compound selectively spares HRAS and NRAS, a profile that distinguishes it from broader pan-RAS approaches and is intended to reduce the toxicity risks associated with non-selective RAS inhibition. Preclinical data cited by Kestrel describe on-target pathway modulation and anti-proliferative activity across multiple human KRAS-mutant tumor models at well-tolerated doses. The clinical development program targets pancreatic ductal adenocarcinoma, colorectal cancer, non-small cell lung cancer, and other KRAS-driven malignancies.
The Phase I study, designated KST-6051-101 and named FALCON, is an open-label, multicenter, dose-escalation trial registered as NCT07458347. Primary objectives include evaluation of safety and tolerability and determination of a recommended dose for expansion. Secondary and exploratory objectives encompass preliminary antitumor activity assessments, pharmacokinetics, and pharmacodynamic readouts. The trial will enroll patients with advanced or metastatic solid tumors harboring KRAS mutations who have progressed on prior standard therapies, with dose escalation followed by expansion cohorts in selected tumor types.
Kestrel received FDA IND clearance for KST-6051 in March 2026, and the first patient was dosed approximately eight weeks later, marking the transition from IND-enabling work into first-in-human evaluation. The company is backed by Pfizer Ventures and Santé Ventures.